Effects of Antidepressants on Sleep

Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the world health surveys. Lancet. 2007;370:851–8.

Greden JF. Unmet need: what justifies the search for a new antidepressant? J Clin Psychiatry. 2002;63(Suppl 2):3–7.

Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des. 2012;18:5802–17.

Le Bon O. Contribution of sleep research to the development of new antidepressants. Dialogues Clin Neurosci. 2005;7:305–13.

Mendlewicz J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry. 2009;10:269–75.

Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65:927–47.

Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry. 2000;8:298–306.

Thase ME. Depression, sleep, and antidepressants. J Clin Psychiatry. 1998;59(Suppl 4):55–65.

Wichniak A, Wierzbicka A, Jernajczyk W. Sleep as a biomarker for depression. Int Rev Psychiatry. 2013;25:632–45.

•• Baglioni C, Nanovska S, Regen W, Spiegelhalder K, Feige B, Nissen C, et al. Sleep and mental disorders: a meta-analysis of polysomnographic research. Psychol Bull. 2016;142:969–90. This large meta-analysis presents polysomnographic (PSG) characteristics of sleep in affective, anxiety, eating, pervasive developmental, borderline and antisocial personality, attention-deficit-hyperactivity disorders and schizophrenia. It has been found that no sleep parameter was exclusively altered in one condition; however, no two conditions shared the same PSG profile.

Abad VC, Guilleminault C. Sleep and psychiatry. Dialogues Clin Neurosci. 2005;7:291–303.

Kaplan KA, Harvey AG. Hypersomnia across mood disorders: a review and synthesis. Sleep Med Rev. 2009;13:275–85.

McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31:180–6.

Kay DB, Dombrovski AY, Buysse DJ, Reynolds CF, Begley A, Szanto K. Insomnia is associated with suicide attempt in middle-aged and older adults with depression. Int Psychogeriatr. 2016;28:613–9.

Schmid DA, Wichniak A, Uhr M, Ising M, Brunner H, Held K, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31:832–44.

Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol. 2002;17(Suppl 1):S27–32.

•• Doghramji K, Jangro WC. Adverse effects of psychotropic medications on sleep. Psychiatr Clin North Am. 2016;39:487–502. This study presents effects of psychotropic medications such as antidepressants, antipsychotics, stimulants, and benzodiazepines on sleep based on analysis of data from US Food and Drug Administration (FDA) study register. It shows that that medication has significant impact on sleep, resulting in both beneficial and adverse effects on sleep.

Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(Suppl 16):27–32.

Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev. 2004;8:19–30.

• Hashimoto T, Shiina A, Hasegawa T, Kimura H, Oda Y, Niitsu T, et al. Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial. Ann General Psychiatry. 2016;15:27. This study demonstrates that mirtazapine as the first-choice antidepressant for current depressive episodes reduces benzodiazepine use in patients with MDD.

Jindal RD, Friedman ES, Berman SR, Fasiczka AL, Howland RH, Thase ME. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol. 2003;23:540–8.

Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev. 2002; CD001026.

Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71:1259–72.

Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378:621–31.

Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le GS, Laredo J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011;26:252–62.

Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol. 2010;25:222–9.

Sowa-Kucma M, Panczyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczen K, et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep. 2017;69:595–601.

• Wilson S, Hojer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol. 2015;29:1085–91. This is the first polysomnographic study presenting effects of vortioxetine on sleep architecture in comparison to placebo and paroxetine.

Rottach KG, Schaner BM, Kirch MH, Zivotofsky AZ, Teufel LM, Gallwitz T, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43:70–5.

Narowska D, Bozek M, Krysiak K, Antczak J, Holka-Pokorska J, Jernajczyk W, et al. Frequent difficulties in the treatment of restless legs syndrome—case report and literature review. Psychiatr Pol. 2015;49:921–30.

Buschkamp JA, Frohn C, Juckel G. Mirtazapine induces nightmares in depressed patients. Pharmacopsychiatry. 2017.

Szaulińska K, Pływaczewski R, Sikorska O, Holka-Pokorska J, Wierzbicka A, Wichniak A, et al. Obstructive sleep apnea in severe mental disorders. Psychiatr Pol. 2015;49:883–95.

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655–79.

Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111.

• Nowicki Z, Grabowski K, Cubala WJ, Nowicka-Sauer K, Zdrojewski T, Rutkowski M, et al. Prevalence of self-reported insomnia in general population of Poland. Psychiatr Pol. 2016;50:165–73. This study shows the high prevalence of insomnia symptoms in a representative sample of Polish general population.

•• Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165:125–33. This publication presents guidelines for chronic insomnia treatment indicating that cognitive-behavioral therapy should be used as a first line treatment.

•• Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13:307–49. This publication contains recent recommendations for clinicians in choosing a specific pharmacological agent for treatment of chronic insomnia in adults.

Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14:9–15.

Riemann D, Spiegelhalder K, Feige B, Voderholzer U, Berger M, Perlis M, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14:19–31.

Mendelson WB, Roth T, Cassella J, Roehrs T, Walsh JK, Woods JH, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Med Rev. 2004;8:7–17.

Wiegand MH. Antidepressants for the treatment of insomnia : a suitable approach? Drugs. 2008;68:2411–7.

Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson A, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.

• Liu Y, Xu X, Dong M, Jia S, Wei Y. Treatment of insomnia with tricyclic antidepressants: a meta-analysis of polysomnographic randomized controlled trials. Sleep Med. 2017;34:126–33. This meta-analysis summarizes the evidence on effects of tricyclic antidepressants on sleep in insomnia patients. TCAs has been found as an effective pharmacological treatment for insomnia, but may cause dangerous side effects.

Thompson W, Quay TA, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: a systematic review. Sleep Med. 2016;22:13–7.

Wichniak A, Jarkiewicz M, Okruszek L, Wierzbicka A, Holka-Pokorska J, Rybakowski JK. Low risk for switch to mania during treatment with sleep promoting antidepressants. Pharmacopsychiatry. 2015;48:83–8.

Jernajczyk W, Sobańska A, Wierzbicka A, Wichniak A, Szatkowska E. The therapy of primary insomnia with citalopram. J Sleep Res. 2006;15(Suppl. 1):154.